We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, FULGENT GENETIC (FLGT - Free Report) closed at $110.38, marking a +1.55% move from the previous day. This change outpaced the S&P 500's 1.14% gain on the day. Elsewhere, the Dow gained 1.35%, while the tech-heavy Nasdaq added 0.99%.
Heading into today, shares of the company had gained 50.6% over the past month, outpacing the Medical sector's loss of 3.27% and the S&P 500's gain of 1.2% in that time.
Wall Street will be looking for positivity from FLGT as it approaches its next earnings report date. This is expected to be March 4, 2021. In that report, analysts expect FLGT to post earnings of $4.41 per share. This would mark year-over-year growth of 10925%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $225.57 million, up 2588.56% from the year-ago period.
Investors might also notice recent changes to analyst estimates for FLGT. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 128.7% higher within the past month. FLGT is currently a Zacks Rank #1 (Strong Buy).
Investors should also note FLGT's current valuation metrics, including its Forward P/E ratio of 8.33. Its industry sports an average Forward P/E of 21.1, so we one might conclude that FLGT is trading at a discount comparatively.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 220, which puts it in the bottom 14% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow FLGT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, FULGENT GENETIC (FLGT - Free Report) closed at $110.38, marking a +1.55% move from the previous day. This change outpaced the S&P 500's 1.14% gain on the day. Elsewhere, the Dow gained 1.35%, while the tech-heavy Nasdaq added 0.99%.
Heading into today, shares of the company had gained 50.6% over the past month, outpacing the Medical sector's loss of 3.27% and the S&P 500's gain of 1.2% in that time.
Wall Street will be looking for positivity from FLGT as it approaches its next earnings report date. This is expected to be March 4, 2021. In that report, analysts expect FLGT to post earnings of $4.41 per share. This would mark year-over-year growth of 10925%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $225.57 million, up 2588.56% from the year-ago period.
Investors might also notice recent changes to analyst estimates for FLGT. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 128.7% higher within the past month. FLGT is currently a Zacks Rank #1 (Strong Buy).
Investors should also note FLGT's current valuation metrics, including its Forward P/E ratio of 8.33. Its industry sports an average Forward P/E of 21.1, so we one might conclude that FLGT is trading at a discount comparatively.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 220, which puts it in the bottom 14% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow FLGT in the coming trading sessions, be sure to utilize Zacks.com.